Adjuvant Zoledronic Acid in High‐Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial

Conclusion.Adjuvant treatment with zoledronic acid did not decrease the recurrence rate of GCTB in this study. The efficacy could not be determined because of the small sample size. Because recurrences, even in the denosumab era, are still an issue, a randomized study exploring the efficacy of zoledronic acid in the adjuvant setting in GCTB is still valid.

Source: The Oncologist - July 16, 2019 Category: Cancer & Oncology Authors: Astrid Lipplaa, Judith R. Kroep, Lizz van der Heijden, Paul C. Jutte, Pancras C.W. Hogendoorn, Sander Dijkstra, Hans Gelderblom Tags: Chinese Edition, Clinical Trial Results Source Type: research